GLP-1-based medications show emerging benefits for heart failure with preserved or mildly reduced ejection fraction.
Background
Heart failure with preserved ejection fraction (HFpEF) represents a significant clinical challenge, often linked to type 2 diabetes and obesity. Current treatments for HFpEF are limited, and the complex interplay of increased lipids, chronic inflammation, and metabolic disturbances contributes to its pathology. Glucagon-like peptide-1 (GLP-1)-based medications, known for their cardiometabolic benefits, offer a promising therapeutic avenue by targeting these interconnected pathophysiological links, aiming to improve morbidity and mortality where standard care falls short.
Study Design
This review systematically summarized and discussed recent studies investigating GLP-1-based medications and their reported heart failure (HF)-related outcomes. The authors focused on synthesizing evidence regarding the utility of these compounds in different HF phenotypes, specifically heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF). The analysis aimed to consolidate findings from various clinical trials and observational studies to assess the current understanding of GLP-1 receptor agonists' impact on HF.
Results
The review found increasing evidence that GLP-1-based medications exert beneficial effects on heart failure (HF) outcomes, particularly in patients with heart failure with preserved ejection fraction (HFpEF). These benefits are likely mediated through the established cardiometabolic actions of GLP-1 receptor agonists, which include improvements in glycemic control, weight loss, and anti-inflammatory effects. The strong pathophysiological links among diabetes, obesity, and heart failure underscore the relevance of these multi-faceted benefits.
The most significant finding indicates that GLP-1-based medications are a promising therapeutic option for improving morbidity and mortality in HFpEF, and potentially in those with mildly reduced ejection fraction (HFmrEF). However, the review also highlighted that the usefulness of GLP-1-based medications in reduced ejection fraction heart failure (HFrEF) remains to be definitively established, suggesting a need for further dedicated research in this specific patient population.
Key Findings
- GLP-1-based medications show beneficial effects on outcomes in heart failure with preserved ejection fraction (HFpEF).
- Potential benefits extend to heart failure with mildly reduced ejection fraction (HFmrEF).
- The role of GLP-1-based medications in heart failure with reduced ejection fraction (HFrEF) is not yet defined.
- GLP-1 receptor agonists address the pathophysiological links among diabetes, obesity, and heart failure.
Why It Matters
This review underscores the growing importance of GLP-1-based medications as a potential cornerstone therapy for patients with heart failure, especially those with co-existing type 2 diabetes and obesity. For clinicians and biohackers, this suggests that GLP-1 receptor agonists could be considered beyond their traditional roles in metabolic disease, offering a dual benefit for both glycemic control and cardiovascular health in specific HF populations. While not yet a universal protocol for all HF types, the evidence strengthens their use in HFpEF and HFmrEF. Further research is crucial to translate these findings into broader clinical guidelines and to clarify their role in HFrEF, potentially leading to new combination therapies or refined treatment algorithms.
glp-1-agonist
heart-failure
hfpef
hf-mr-ef
obesity
type-2-diabetes